Brett Scott
Contributor since: 2007
Latest Articles
Understanding Cost of Capital in Biotechs' Valuation
Will the Clouds Clear for Amgen?
Gilead Keeps Going Strong
Correction and Clarification to Tysabri Post
Elan, Biogen Idec Won't Gain Much from Tysabri Approval
Investors May Prefer to Stay Away from DNA
Forecast for ViroPharma's Pipeline: Mostly Shiny
FDA Sets Date for Theravance Drug Review
A Win-Win for Isis, Genzyme in Cholesterol Drug Deal
Celgene Puts Drug Scare Behind It
Amgen's Bone Density Drug Needs to Prove Itself
Three Reasons To Turn To Biotech In A Messy Market
Staph Buzz Spotlights Cubist, Pfizer, Encysive
Gilead Continues To Shine, But Watch The Competition
3 Positives From Vanda's Conference Call
NeurogesX, Vanda Would Do Well To Find Themselves A Partner
Two Important Lessons to be Learned from Sonus
Celgene Offers Investors The Growth They Want
Is Biotech on the Verge of a Breakout?
Now's The Time To Hop Aboard NeurogesX
Sonus Is Undervalued At $4 - Call Options Are Attractive
Vanda Pharmaceuticals: Finding Reassurance In Institutional Investors and Fair Value Calculations
Helicos: To Buy or Not To Buy?
Three Reasons to Be Optimstic on NeurogesX
Vanda Pharmaceuticals' Pipeline Nearing FDA Stage
Ziopharm: Too Early To Make A Call
Neurogesx: A Speculative Biotech Investment
Genentech Suffering From A Lack of Short-Term Catalysts
DepoMed Demonstrates The Risks Of Small Biotech
Celgene, Genentech, Gilead: Is Biotech Weakness Creating A Buying Opportunity?